SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors

被引:8
|
作者
Qu, D. [1 ]
Yan, A. [1 ]
Zhang, J. S. [2 ]
机构
[1] Beijing Univ Chem Technol, State Key Lab Chem Resource Engn, Beijing, Peoples R China
[2] Renmin Univ China, High Sch, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Human epidermal growth factor receptor-2 (HER2) inhibitor; structure-activity relationship (SAR); quantitative structure-activity relationship (QSAR); support vector machine (SVM); random forest (RF); multiple linear regression (MLR); ORALLY-ACTIVE INHIBITORS; NEUTRAL; 5-SUBSTITUTED; 4-ANILINOQUINAZOLINES; PYRROLOTRIAZINE DUAL INHIBITORS; TYROSINE KINASE INHIBITORS; BIOLOGICAL EVALUATION; IRREVERSIBLE INHIBITORS; ERBB RECEPTORS; MULTITARGETED INHIBITORS; PYRAZOLINE DERIVATIVES; MOLECULAR DOCKING;
D O I
10.1080/1062936X.2017.1284898
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this paper, structure-activity relationship (SAR, classification) and quantitative structure-activity relationship (QSAR) models have been established to predict the bioactivity of human epidermal growth factor receptor-2 (HER2) inhibitors. For the SAR study, we established six SAR (or classification) models to distinguish highly and weakly active HER2 inhibitors. The dataset contained 868 HER2 inhibitors, which was split into a training set including 580 inhibitors and a test set including 288 inhibitors by a Kohonen's self-organizing map (SOM), or a random method. The SAR models were performed using support vector machine (SVM), random forest (RF) and multilayer perceptron (MLP) methods. Among the six models, SVM models obtained superior results compared with other models. The prediction accuracy of the best model (model 1A) was 90.27% and the Matthews correlation coefficient (MCC) was 0.80 on the test set. For the QSAR study, we chose 286 HER2 inhibitors to establish six quantitative prediction models using MLR, SVM and MLP methods. The correlation coefficient (r) of the best model (model 4B) was 0.92 on the test set. The descriptors analysis showed that HAccN, lone pair electronegativity and electronegativity were closely related to the bioactivity of HER2 inhibitors.
引用
收藏
页码:111 / 132
页数:22
相关论文
共 50 条
  • [41] Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target
    De Vita, F.
    Giuliani, F.
    Silvestris, N.
    Catalano, G.
    Ciardiello, F.
    Orditura, M.
    CANCER TREATMENT REVIEWS, 2010, 36 : S11 - S15
  • [42] The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs)
    Duran, C. Garcia
    Musacchio, L.
    Mazzeo, R.
    Carita, L.
    Jimenez, J.
    Bejar, J. F. Grau
    Illescas, D. G.
    Fasani, R.
    Madrid, L. Farinas
    Villacampa, G.
    Oaknin, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S590 - S591
  • [43] Impact of the 2018 ASCO/CAP HER2 focused update on human epidermal growth factor receptor-2 (HER2) testing in breast cancer: A retrospective review of a single institutional cohort
    Hicks, D. G.
    D'Aguiar, M.
    Henry, J.
    McMahon, L.
    Buscaglia, B.
    Turner, B.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Clinical impact of epidermal growth factor receptor (EGFR) coexpression in early breast cancer with human epidermal growth factor receptor 2 (HER2) overexpression
    Park, S.
    Cho, E.
    Shin, Y.
    Hong, S.
    Lee, M.
    Park, Y.
    Nam, S.
    Yang, J.
    Choi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Draft recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer will decrease HER2 positivity rates
    Johnson, Eric
    Gulbahce, Evin
    CANCER RESEARCH, 2018, 78 (04)
  • [46] Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
    Abunada, Aya
    Sirhan, Zaid
    Thyagarajan, Anita
    Sahu, Ravi P.
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2023, 14 (05): : 198 - 202
  • [47] A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion
    Fichter, Christiane Daniela
    Przypadlo, Camilla Maria
    Buck, Achim
    Herbener, Nicola
    Riedel, Bianca
    Schaefer, Luisa
    Nakagawa, Hiroshi
    Walch, Axel
    Reinheckel, Thomas
    Werner, Martin
    Lassmann, Silke
    JOURNAL OF PATHOLOGY, 2017, 243 (04): : 481 - 495
  • [48] Human epidermal growth factor receptor families (EGFR, HER2) and survival in colorectal adenocarcinoma
    Molaei, M.
    Pejhan, S.
    Emami, S.
    Ghiasi, S.
    Mashayekhi, R.
    Zali, M.
    Motlagh, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 90 - 90
  • [49] Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
    Riecke, Kerstin
    Witzel, Isabell
    BREAST CARE, 2020, 15 (06) : 579 - 585
  • [50] Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
    Siddiqui, Mohammad R.
    Railkar, Reema
    Sanford, Thomas
    Crooks, Daniel R.
    Eckhaus, Michael A.
    Haines, Diana
    Choyke, Peter L.
    Kobayashi, Hisataka
    Agarwal, Piyush K.
    SCIENTIFIC REPORTS, 2019, 9 (1)